Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 8/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296802 | 0.86 | ALOX15 (0.59) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL1202083 | 0.86 | ALOX15 (0.59) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3707866 | 0.86 | RAB9A (0.61) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL31609642 | 0.83 | RAB9A (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL7920033 | 0.83 | RAB9A (0.58) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL2109109 | 0.82 | RAB9A (0.60) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30104780 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL831147 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4067752 | 0.80 | HSD17B10 (0.39) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL11148656 | 0.78 | HCRTR1 (0.53) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY5, ADCY2 | KDM4E 2032/4885ALDH1A1 327/4885RAB9A 1792/4885 |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | KDM4E 688/4885ALDH1A1 3043/4885RAB9A 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.